The incidence of lymph node metastasis (N3: 7.3% vs 3.1%, 3.9% and 4.4%, respectively; P < 0.001) and percentage of IIIA stage (15.9% vs 10.6%, 13.1% and 11.8%, respectively; P < 0.001) was higher in the HER2‐enriched patients than in the luminal‐A, luminal‐B and triple‐negative. The gene discussed is ERBB2; the disease is metastatic malignant neoplasm in the lymph nodes.